



UNITED STATE DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR			ATTORNEY DOCKET NO.	
08/908,469	08/06/ 9 7	BACA		М	P1093P1	
HM22/0811			一		EXAMINER	
GENENTECH	INC.	"""		UNGAR,S		
1 DNA WAY	SPANCTOCO CA	94080-4990		ART UNIT	PAPER NUMBER	
COURT OHN	INDIANTOCA CH	94030-49 9 0		1642	20	
				DATE MAILED:	08/11/00	

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trad marks

Office Action Summary

Application No. 08/908,469

Appant(s)

Examiner

Ungar

Group Art Unit 1642

Baca et al

Ш	Ш	Ш		Ш	H

X Responsive to communication(s) filed on Nov 22, 1999						
☑ This action is FINAL.						
☐ Since this application is in condition for allowance except for for in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.	rmal matters, prosecution as to the merits is closed .D. 11; 453 O.G. 213.					
A shortened statutory period for response to this action is set to exis longer, from the mailing date of this communication. Failure to rapplication to become abandoned. (35 U.S.C. § 133). Extensions 37 CFR 1.136(a).	espond within the period for response will cause the					
Disposition of Claims						
	is/are pending in the application.					
Of the above, claim(s) 1-33 and 39-42						
Claim(s)						
Claim(s)						
☐ Claims						
Application Papers						
☐ See the attached Notice of Draftsperson's Patent Drawing Re	eview, PTO-948.					
☐ The drawing(s) filed on is/are objected to						
☐ The proposed drawing correction, filed on						
☐ The specification is objected to by the Examiner.						
☐ The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. § 119						
Acknowledgement is made of a claim for foreign priority und	er 35 U.S.C. § 119(a)-(d).					
☐ All ☐ Some* ☐ None of the CERTIFIED copies of the priority documents have been						
☐ received.						
received in Application No. (Series Code/Serial Number						
received in this national stage application from the International Bureau (PCT Rule 17.2(a)).						
*Certified copies not received:						
Acknowledgement is made of a claim for domestic priority ur	nder 35 U.S.C. § 119(e).					
Attachment(s)						
□ Notice of References Cited, PTO-892						
☐ Information Disclosure Statement(s), PTO-1449, Paper No(s).☐ Interview Summary, PTO-413						
☐ Notice of Draftsperson's Patent Drawing Review, PTO-948						
☐ Notice of Informal Patent Application, PTO-152						
SEE OFFICE ACTION ON THE F	FOLLOWING PAGES					

Serial No: 08/908,469 Page 2

Art Unit: 1642

1. The request filed on November 22, 1999 for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) based on parent Application No. 08/908,469 is acceptable and a CPA has been established. An action on the CPA follows.

- The Claims 1-42 are pending and claims 1-33 and 39-42 remain withdrawn from consideration for the reasons set forth in Paper No. 8. Claims 34-38 are currently under examination.
- 3. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- 4. Because all claims are drawn to the same invention claimed in parent application Serial No. 08/908,469 and no additional arguments or amendments to the claims have been submitted, claims 34-38 remain rejected for the reasons previously disclosed in Paper No. 13, mailed April 14, 1999 as follows:
- 5. The following rejections are being maintained:

Claim Rejections - 35 USC § 103

6. Claims 34-38 remain rejected under 35 USC 103 for the reasons previously set forth in Paper No. 8, Section 4, pages 2-4.

Applicant argues that (a) the skilled artisan would not have a reasonable expectation of success based on Ferrara alone that one could form a humanized form of the murine anti-VEGF antibody of Ferrara that would have a binding affinity of within ten-fold of the murine antibody, as claimed, (b) the instant invention provides the unexpected result of a humanized antibody for VEGF having a binding affinity of no more than 1 x 10⁻⁸, © the binding affinity of the humanized hu2.0

Serial No: 08/908,469 Page 3

Art Unit: 1642

murine antibody had 1000 fold reduction in affinity over the murine antibody. The arguments have been noted but have not been found persuasive because (a') it was well within the level of the skill in the art at the time Ferrara's invention was made to use conventional methods to produce a humanized murine anti-VEGF antibody with a binding affinity of 1 x 10⁻⁹ as expressly suggested by Ferrara, further, the claims are not limited to "a binding affinity of within ten-fold of the murine antibody", (b') it is clear that a binding affinity of 1 x 10⁻⁹ is a Kd value of "no more than about 1 x 10⁻⁸" and since it was expressly suggested by Ferrara and conventional methods were known to produce the molecule it is clear that the results of the instant invention are not unexpected, (c') applicant is arguing limitations not recited in the claims as presently constituted.

- 7. All other objections and rejections recited in Paper No. 8 are withdrawn.
- 8. No claims allowed.
- This is a CPA of applicant's earlier application S.N. 08/908469. All claims are drawn to the same invention claimed in the earlier application and, although applicant has filed request for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d), no Amendment or Response containing either arguments drawn to the instant rejections or amendments to the claims has been submitted. Thus, THIS ACTION IS MADE FINAL even though it is a first action in this case. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). See M.P.E.P. § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 C.F.R. § 1.136(a).

Serial No: 08/908,469 Page 4

Art Unit: 1642

A SHORTENED STATUTORY PERIOD FOR RESPONSE TO THIS FINAL ACTION IS SET TO EXPIRE THREE MONTHS FROM THE DATE OF THIS ACTION. IN THE EVENT A FIRST RESPONSE IS FILED WITHIN TWO MONTHS OF THE MAILING DATE OF THIS FINAL ACTION AND THE ADVISORY ACTION IS NOT MAILED UNTIL AFTER THE END OF THE THREE-MONTH SHORTENED STATUTORY PERIOD, THEN THE SHORTENED STATUTORY PERIOD WILL EXPIRE ON THE DATE THE ADVISORY ACTION IS MAILED, AND ANY EXTENSION FEE PURSUANT TO 37 C.F.R. § 1.136(a) WILL BE CALCULATED FROM THE MAILING DATE OF THE ADVISORY ACTION. IN NO EVENT WILL THE STATUTORY PERIOD FOR RESPONSE EXPIRE LATER THAN SIX MONTHS FROM THE DATE OF THIS FINAL ACTION.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan Ungar, PhD whose telephone number is (703) 305-2181. The examiner can normally be reached on Monday through Friday from 7:30am to 4pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Paula Hutzell, can be reached at (703) 308-4310. The fax phone number for this Art Unit is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Effective, February 7, 1998, the Group and/or Art Unit location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1642.

Serial No: 08/908,469

Art Unit: 1642

Susan Ungar

August 9, 2000

SUSAN UNGAR, PH.D PRIMARY EXAMINER